CG
TCRT icon

Clinton Group’s Alaunos Therapeutics TCRT Stock Holding History

Clinton Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-188
Closed -$209K – 1037
2016
Q1 		$209K Buy
+188
New +$192K 0.01% 810

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Clinton Group's TCRT Position: Q2 2016 in Review

Clinton Group sold out of Alaunos Therapeutics (TCRT) in Q2 2016, closing a stake of 188 shares — an estimated $209K sold.

Clinton Group first reported a position in TCRT in Q1 2016 and held it in 1 quarter. The position peaked at $209K in Q1 2016. 154 funds tracked by Wall St. Rank hold TCRT as of Q2 2016.

  • Clinton Group reported no remaining Alaunos Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Clinton Group sold 188 Alaunos Therapeutics shares in Q2 2016, an estimated $209K.
  • Clinton Group first reported a position in Alaunos Therapeutics in Q1 2016 and held it in 1 quarter.
  • Clinton Group's Alaunos Therapeutics position peaked at $209K in Q1 2016.
  • 154 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2016.

Based on Clinton Group's 13F filing for Q2 2016, filed 12 Aug 2016.